Use of Systemic Antineoplastic Drug Therapy after Regulatory Agency Approval

Publisher： Karger

E-ISSN： 1423-0232|72|3-4|145-146

ISSN： 0030-2414

Source： Oncology, Vol.72, Iss.3-4, 2007-12, pp. : 145-146

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Optimizing the Use of Oral Anti-Neoplastic Drug Therapy

By  

Oncology, Vol. 84, Iss. 2, 2012-10 ,pp. : 65-66

Karger

Access to resources Recommend Favorite

Ethical Considerations in Orphan Drug Approval and Use

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 2, 2012-08 ,pp. : 153-155

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?

By  

Case Reports in Oncology, Vol. 3, Iss. 1, 2010-03 ,pp. : 59-62

Karger

Access to resources Recommend Favorite

Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population‐based analysis

By  

CANCER, Vol. 119, Iss. 19, 2013-10 ,pp. : 3489-3495

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vaccine‐Derived Immunity in Children With Cancer—Analysis of Anti‐Tetanus and Anti‐Diphtheria Antibodies Changes after Completion of Antineoplastic Therapy

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 12, 2015-12 ,pp. : 2108-2113

John Wiley & Sons Inc

Access to resources Recommend Favorite